Cardiogenomics testing panels market seen reaching $2.78 billion by 2030

The cardiogenomics testing panels market is projected to expand from $1.55 billion in 2025 to $2.78 billion by 2030, driven by genetic testing advances, rising inherited cardiovascular disease awareness and broader use of precision medicine. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Cardiogenomics testing panels are becoming a bigger part of cardiovascular care as providers look for earlier diagnosis, better risk stratification and more personalized treatment. - The market’s projected growth signals rising demand for tests that can identify inherited heart risks before symptoms worsen. - Wider adoption could improve outcomes for conditions such as cardiomyopathies, arrhythmias and familial hypercholesterolemia.

What happened: - The Business Research Company said the global cardiogenomics testing panels market is expected to grow from $1.55 billion in 2025 to $1.75 billion in 2026. - The market is forecast to reach $2.78 billion by 2030. - The report puts the market on a 12.6% CAGR in the historical period and 12.3% CAGR through 2030. - The report was published July 30, 2026. - The company also released a free sample of the report and the full market report here.

The details: - Cardiogenomics testing panels examine multiple genes at once to detect inherited cardiovascular disease risks. - The panels are used to support early diagnosis, personalized therapies and family risk assessment. - The report links market growth to rising cardiovascular disease prevalence, limited access to genetic testing services, broader awareness of inherited cardiac disorders, continued use of traditional diagnostic methods and high early sequencing costs. - The report says next-generation sequencing, artificial intelligence, bioinformatics, multi-gene and whole-exome panels, and government support for precision medicine will help drive future growth. - The report also points to growing demand for tailored cardiovascular treatments. - The market report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated key technology and future-trend analysis.

Between the lines: - The report reflects a broader shift in cardiovascular care from broad diagnostic approaches to genetics-led prevention and treatment. - Rising healthcare spending appears to be creating room for more advanced testing, especially where health systems are investing in early detection tools. - Inherited cardiovascular disease is still likely underdiagnosed in many settings, which leaves room for panel testing to expand. - The report cites Blackpool in the UK, where cardiovascular disease deaths rose to 185 in 2023 from 178 in 2022, as an example of the public health burden. - The UK Office for National Statistics reported total healthcare expenditure rose 5.6% nominally in 2023 from 2022.

What's next: - North America is expected to remain the largest regional market because of advanced healthcare infrastructure and strong adoption of innovative diagnostics. - Asia-Pacific is forecast to grow fastest as healthcare investment rises and awareness of genetic testing increases. - More adoption of multi-gene and whole-exome panels could widen the market beyond specialty centers and into broader clinical use.

The bottom line: - Cardiogenomics testing panels are moving from niche genetic tools toward a larger precision-medicine market with strong growth through 2030.